Alcon ups ante in Novartis scrap; Zenotech shares slump on Daiichi Sankyo court decision

@FierceBiotech: XenoPort's lead program suffers another big setback. Article | Follow @FierceBiotech

@JohnCFierce: Fewer IPOs, smaller VC funds. Lean and mean will be the dominant fashion for Venrock's new, smaller fund. Article | Follow @JohnCFierce

> Alcon's independent directors are upping the ante in their squabble with Novartis. The directors committee (IDC) has now set up a $50 million litigation trust to make sure that minority shareholders get a good deal in selling their shares to the Swiss drugmaker, Reuters reports. Report

> Shares of India's Zenotech Laboratories slumped following a court ruling that Daiichi Sankyo shouldn't be forced to increase its $16.7 million offer for a stake in the biotech. Story

> Optimer Pharmaceuticals has snared a $500,000 milestone payment from Cempra. Report

> Germany's Merck KGaA has gained EU approval to complete its deal to buy the life sciences tool company Millipore. Story

> The FDA has approved Kiadis Pharma's IND app to start the pivotal clinical study for its product ATIR in the United States. Release

> The FDA has provided orphan drug status to Synageva for SBC-102, an enzyme replacement therapy in development to treat Lysosomal Acid Lipase Deficiency. Report

Special Report: Top 10 Pharma CEO salaries of 2009

And Finally... For the fifth time in the past year a woman who had sexual contact with a member of the U.S. military contracted the vaccinia virus after being exposed to the puncture site for a smallpox vaccine. Story

Suggested Articles

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

Creating new, successful central nervous system drugs is tough, and Lundbeck knows this better than most after canning an internal CNS effort.

After seeing later stage trials come through in obesity, Novo Nordisk is canning two projects that were aiming to help reduce patients’ weight.